| Q60919787 | An advanced clinician practitioner in arthritis care can improve access to rheumatology care in community-based practice |
| Q91510424 | Antirheumatic Medicine Prescribing Patterns and Direct Medicine Costs in the South African Private Health Sector |
| Q26798332 | Burden of illness of rheumatoid arthritis in Latin America: a regional perspective |
| Q38645102 | Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis |
| Q34739465 | Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s |
| Q47998668 | Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending. |
| Q33841358 | Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada |
| Q39646869 | Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study |
| Q48278236 | Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry. |
| Q92551580 | Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry |
| Q92375526 | Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis |
| Q36182309 | Depression is a stronger predictor of the risk to consider work disability in early arthritis than disease activity or response to therapy |
| Q38650525 | Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable Analysis |
| Q39191669 | Economic burden of long-term care of rheumatoid arthritis patients in Hungary |
| Q38878560 | Effectiveness of an integrated care intervention on supervisor support and work functioning of workers with rheumatoid arthritis |
| Q26750454 | Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis |
| Q35995603 | Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up |
| Q56794417 | Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review |
| Q39003173 | Healthcare costs associated with elderly chronic pain patients in primary care |
| Q36243390 | Improving patient flow of people with rheumatoid arthritis has the potential to simultaneously improve health outcomes and reduce direct costs |
| Q36842488 | Indirect costs of rheumatoid arthritis |
| Q91786581 | Major Challenges in Rheumatology: Will We Ever Treat Smarter, Instead of Just Harder? |
| Q89867781 | Patient, Rheumatologist and Therapist Perspectives on the Implementation of an Allied Health Rheumatology Triage (AHRT) Initiative in Ontario Rheumatology Clinics |
| Q57286440 | Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data |
| Q38893192 | Pharmacoeconomics of Biosimilars: What Is There to Gain from Them? |
| Q38647397 | Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10. |
| Q41168364 | Power of national economy, disease control and employment status in patients with RA-an analytical multi-site ecological study |
| Q45338711 | Preventing disability in inflammatory bowel disease |
| Q47784999 | Productivity loss of Japanese patients with rheumatoid arthritis - A cross-sectional survey |
| Q90614968 | Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study |
| Q48188706 | Temporal trends and regional disparity in rheumatoid arthritis and gout hospitalizations in Sweden, 1998-2015. |
| Q36059239 | The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries |
| Q99608910 | The relationship between dietary patterns and rheumatoid arthritis: a case-control study |
| Q30316308 | Treat to participation : Position paper of the German Society for Rheumatology on sustained improvement of functional health of patients with rheumatic and musculoskeletal diseases |
| Q39450570 | Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada From 2000 to 2011. |
| Q39248083 | Welfare costs in patients with rheumatoid arthritis and their partners compared with matched controls: a register-based study |
| Q52852176 | [Rheumatology - Integration into student training (RISA) : Current structure of clinical rheumatology in German universities (RISA III)]. |
| Q52850371 | [Treat to target and personalized medicine (precision medicine)]. |